They observed improvements in several pathways, such as liver biochemistry and markers of inflammation, hepatic and systemic insulin sensitivity, insulin sensitivity and lipolysis, hepatic de novo lipogenesis, and hepatic steatosis. The gene discussed is INS; the disease is fatty liver disease.